Skip to main content
Fig. 7 | Cancer Nanotechnology

Fig. 7

From: Dye-doped silica nanoparticles: synthesis, surface chemistry and bioapplications

Fig. 7

(adapted from Tivnan et al. (2012))

Delivering therapeutic microRNA with silica nanoparticles for cancer therapy. Anti-disialoganglioside (GD2) sensitised DDSNs were used to treat neuroblastoma in mouse xenograft model. The NPs contained a NIR dye as a contrast reagent and were loaded with therapeutic miRNA34-a. a (left) Antibody-coated NPs containing a scrambled RNA sequence or (right) miRNA34-a were injected into GD2-positive NB1691 tumours and only those containing miRNA34-a reduced tumour size, b and was also the case for GD2-positive SK-N-AS tumours. c The NPs only tended to accumulate in the tumour tissue and avoided retention in organs like the liver and spleen and d biodistribution was quantified by fluorescence

Back to article page